-0.01%
-4.42%
4.95%
-0.89%
4.57%
-7.71%
31.98%
AI Spotlight on QIA
Company Description
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables.Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.
It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati.The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Market Data
| Last Price | 42.9 |
| Change Percentage | -0.01% |
| Open | 42.91 |
| Previous Close | 42.9 |
| Market Cap ( Millions) | 9269 |
| Volume | 414206 |
| Year High | 47.36 |
| Year Low | 37.63 |
| M A 50 | 44.35 |
| M A 200 | 42.04 |
Financial Ratios
| FCF Yield | 4.73% |
| Dividend Yield | 2.96% |
| ROE | 2.59% |
| Debt / Equity | 54.39% |
| Net Debt / EBIDTA | 267.28% |
| Price To Book | 2.81 |
| Price Earnings Ratio | 106.79 |
| Price To FCF | 21.14 |
| Price To sales | 4.94 |
| EV / EBITDA | 30.1 |
News
- Jan -30 - Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Jan -30 - Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
- Jan -17 - Strategic Collaborations Aid QGEN Stock Amid Competition
- Jan -16 - QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
- Jan -16 - GMAB vs. QGEN: Which Stock Is the Better Value Option?
- Jan -15 - BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?
- Jan -15 - QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
- Jan -12 - QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
- Jan -10 - Qiagen scoops FDA clearance for gastrointestinal panel
- Jan -10 - QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
- Jan -09 - QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
- Jan -09 - Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
- Jan -08 - QGEN Stock Might Rise Following Partnership With Genomics England
- Jan -07 - QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
- Dec -30 - Why Is Qiagen N.V. (QGEN) Among the Top CRISPR Stocks to Invest In?
- Dec -30 - New Product Offerings Support QIAGEN's Shares Amid Currency Woes
- Dec -13 - QIAGEN Stock Gains Following the Latest Launch of IPA Interpret
- Dec -12 - QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
- Dec -12 - Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?
- Dec -09 - QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Consumables and Related
Expected Growth : 5 %
What the company do ?
Consumables and Related from Qiagen N.V. refers to molecular biology products, such as DNA and RNA purification kits, PCR assays, and sequencing technologies.
Why we expect these perspectives ?
Qiagen's Consumables and Related segment growth is driven by increasing demand for molecular diagnostics, particularly in infectious disease testing and companion diagnostics. Additionally, the company's expanding portfolio of assays and instruments, such as the QIAstat-Dx and NeuMoDx systems, is contributing to growth. Furthermore, Qiagen's strategic partnerships and acquisitions are enhancing its market presence and driving revenue growth.
Segment n°2 -> Instrumentation
Expected Growth : 7 %
What the company do ?
Instrumentation from Qiagen N.V. refers to molecular diagnostic instruments and consumables for sample preparation, PCR, and sequencing, enabling researchers to analyze biological samples.
Why we expect these perspectives ?
Qiagen N.V.'s 7% growth driven by increasing demand for molecular diagnostics, particularly in infectious disease testing and personalized healthcare. Expanding presence in emerging markets, strategic partnerships, and innovative product launches also contribute to growth. Additionally, the company's focus on digitalization and automation of laboratory workflows enhances operational efficiency and drives revenue.
Qiagen N.V. Products
| Product Range | What is it ? |
|---|---|
| QIAprep& | A series of automated nucleic acid purification systems for high-throughput laboratories |
| QIAGEN PCR Systems | A range of thermal cyclers and real-time PCR systems for amplification and detection of nucleic acids |
| GeneReader NGS System | A next-generation sequencing (NGS) system for targeted gene panels and whole-exome sequencing |
| QIAseq Targeted DNA Panels | Pre-designed and custom panels for targeted DNA sequencing |
| QuantiFERON-TB Gold | A diagnostic test for latent tuberculosis infection |
| artus molecular diagnostics | A range of CE-IVD marked PCR assays for infectious disease detection |
| QIAGEN Bioinformatics | A suite of bioinformatics tools and software for NGS data analysis |
| CLC Genomics Workbench | A bioinformatics platform for NGS data analysis and interpretation |
Qiagen N.V.'s Porter Forces
Threat Of Substitutes
Qiagen N.V. operates in the life sciences industry, which is characterized by a moderate threat of substitutes. While there are alternative products and services available, Qiagen's proprietary technologies and strong brand recognition help to mitigate this threat.
Bargaining Power Of Customers
Qiagen N.V. has a diverse customer base, including academic and government institutions, pharmaceutical and biotechnology companies, and clinical laboratories. While customers have some bargaining power, Qiagen's strong brand and product offerings help to maintain a balance of power.
Bargaining Power Of Suppliers
Qiagen N.V. has a diverse supplier base, and the company is not heavily dependent on any single supplier. This reduces the bargaining power of suppliers, giving Qiagen more control over its supply chain.
Threat Of New Entrants
The life sciences industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to challenge Qiagen's market position.
Intensity Of Rivalry
The life sciences industry is highly competitive, with several established players competing for market share. Qiagen N.V. faces intense competition from companies such as Thermo Fisher Scientific, Illumina, and Agilent Technologies, which can lead to pricing pressure and increased marketing expenses.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 28.69% |
| Debt Cost | 4.39% |
| Equity Weight | 71.31% |
| Equity Cost | 6.03% |
| WACC | 5.56% |
| Leverage | 40.24% |
Qiagen N.V. : Quality Control
Qiagen N.V. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CBAV.MC | Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics … |
| ERF.PA | Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, … |
| SYAB.DE | SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers … |
| BIM.PA | bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers … |
| DIA.MI | DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Clínica Baviera
A-Score
1-Year Total Return ->
🥈
Synlab
A-Score
1-Year Total Return ->
🥉
DiaSorin
A-Score
1-Year Total Return ->
4
Qiagen
A-Score
1-Year Total Return ->
5
bioMérieux
A-Score
1-Year Total Return ->
6
